Borba et al., JAMA Network Open,
doi:10.1001/jamanetworkopen.2020.8857 (Peer Reviewed)
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)
Comparison of typical CQ dosage with high dosage CQ (600mg CQ twice daily for 10 days), showing higher mortality with high dosage, OR 2.8 [0.9 - 8.5] when controlled by age in multivariate analysis.
Increased incidence of prolonged QT and death in high dose treatment arm. Patients >75 only enrolled in high dose arm, age of high dose arm significantly higher than low dose arm (
p=0.02). Very sick at baseline, 46% in ICU, 89% on oxygen therapy (this information can be found in the preprint [1]).
Borba et al., 4/16/2020, peer-reviewed, mean age 51.1, 28 authors.